Latest news with #Werner
West Australian
4 days ago
- Business
- West Australian
New-look board tins up EV Resources for Mexican antimony tilt
EV Resources is doubling down on its high-grade Los Lirios antimony mine in Mexico, with a revamped board and a fresh round of funding to fast-track the project towards production. The company has welcomed two seasoned mining veterans to its board, with Shane Menere stepping in as non-executive chairman and Justin Werner joining as a non-executive director. The incoming heavyweights have opened their shoulders – and their wallets – to invest $200,000 total in a $650,000 capital raise, affirming their belief in the company and its flagship – and now sole - project. Menere is a mining entrepreneur with a quarter century's worth of experience, including his current role as founder and chief executive officer of ASX-listed explorer Far East Gold. Meanwhile, Werner currently steers the ship at the world's largest listed pure nickel producer, Nickel Industries. As managing director, he has taken the company to a $3 billion market cap and some 130,000 tonnes per annum of nickel output. The pair's arrival sees Luke Martino shift from chairman to non-executive director, ensuring continuity as EVR sharpens its antimony strategy. The new directors have also elected to receive their salaries as shares, allowing for all-important funds to be focussed on bringing Los Lirios into immediate production while antimony prices are at all-time highs. As remuneration, Werner and Menere will receive 20 million shares and 20 million options each at a 0.3 cents excise price with a one-year expiry, pending shareholder approval. The funds will fuel the restart of Los Lirios, a 1652-hectare project in Oaxaca, Mexico, which has three historical small open pits. EVR holds a 70 per cent stake in the project. Los Lirios has climbed the ranks to become EVR's cornerstone and sole asset. The historical open pits and underground workings delivered high-grade antimony ore until the 1970s, returning assays as high as 62 per cent and 62.99 per cent antimony. The company has 30-kilogram bulk antimony samples undergoing ore characterisation to pave the way for gravity-based recovery tests. With talks underway for a pilot processing plant, EVR is eyeing a rapid production restart to capitalise on antimony's soaring demand, driven by China's export bans and its critical role in semiconductors, ammunition and solar panels. To streamline its focus, EVR made a tough call to relinquish its former flagship Parag copper-molybdenum porphyry project in Peru. Despite stellar drilling results, such as 18 metres at 1.7 per cent copper and 0.4 per cent molybdenum from 11m. The board deemed Parag's funding needs were too hefty for the current market conditions and instead opted to conserve cash and channel resources into Los Lirios' near-term potential. The company has recently made several divestments, such as the Yanamina gold-silver project, which it sold for up to $9.3 million and quickly flipped its Coyote Creek antimony project for a $450,000 profit. The deals have armed the company with the cash and future payments it needs to advance its Mexican mine to regional prominence. While EVR cautions that exploration and development risks remain, including uncertainties around mineralisation economics and financing, the new board's pedigree and strategic focus signal a clear intent. With drill bits ready to spin and a pilot plant in sight, EV Resources is shaping up as a near-term player in a red-hot antimony market. Is your ASX-listed company doing something interesting? Contact:
Yahoo
5 days ago
- Sport
- Yahoo
Matthias Jaissle RB Leipzig's back up option to Ole Werner
kicker reports that Al Ahli coach Matthias Jaissle is the backup option for RB Leipzig if they fail to complete the signing of Ole Werner. Negotiations over Werner are currently at a standstill as Werder Bremen are demanding a fee of around €6m for their former head coach. Leipzig has little interest in paying such a fee for Werner, and there have yet to be negotiations this week over the coach. Advertisement This means Leipzig has begun to look for alternatives, and Jaissle is one of them. Leipzig has already held talks with the former Red Bull Salzburg head coach. Despite leaving Salzburg in 2023, Jaissle has had a successful spell in Saudi Arabia, leading Al-Ahli to the AFC Champions League. Leipzig is currently experiencing the same thing that Bayern Munich did last summer. The fact that they have failed to qualify for European competition makes them very unattractive to several high-profile managers, while the fact that their best players also want to leave does not help. GGFN | Jack Meenan
Indianapolis Star
11-06-2025
- Business
- Indianapolis Star
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model
Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival. Building on previous data in Werner syndrome, showing Telomir-1 reset the epigenetic clock, extended telomere length, restored gene expression, reversed muscle loss, and rescued survival-alongside data in Age Related Macular Degeneration (AMD) demonstrating retinal regeneration and restored vision-the drug continues to show broad regenerative potential across rare genetic degenerative diseases MIAMI, FL / ACCESS Newswire Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the 'Company,' a preclinical-stage biotechnology company focused on reversing biological aging and degenerative diseases, today announced compelling new preclinical data demonstrating that its lead drug candidate, Telomir-1, significantly reversed neurological, hepatic and kidney symptoms in a clinically relevant animal model of Wilson's disease. Wilson's disease is a rare and potentially fatal genetic disorder caused by mutations in the ATP7B gene, which impair the body's ability to eliminate excess copper. As copper builds up-primarily in the liver and brain-it leads to inflammation, tissue damage, and multi-organ dysfunction. Patients may experience liver failure, psychiatric disturbances, tremors, and progressive neurological decline. Current treatments involve lifelong copper chelation or liver transplantation, highlighting the urgent need for safer, disease-modifying therapies. These new results build on earlier in vitro studies that confirmed Telomir-1's high binding affinity for copper and its ability to exchange and regulate key ions. The current in vivo findings now confirm that Telomir-1's copper-regulating properties translate into meaningful behavioral, physiological and histological improvements in a genetic animal model of Wilson's disease. In the ATP7B C271X -/- zebrafish model, which mimics human Wilson's disease Telomir-1 demonstrated dose-dependent and statistically significant reversal of major disease features: Key Findings from the Study: Up to a 4- to 5-fold reduction in episodic tremor events Normalization of swim distance, swim velocity, and exploratory behavior Reversal of ataxia-like motor behaviors (e.g., abnormal body bends and turn angles) Approximately 50% reduction in copper accumulation in dry liver tissue Marked improvement in liver and kidney histopathology, with liver and kidney scores reduced to near-normal levels Normalization of ALT, AST, and bilirubin-three critical liver biomarkers. ALT and AST are enzymes elevated during liver injury, while bilirubin builds up when detoxification is impaired. Telomir-1 restored these to wild-type levels, indicating protection of liver function and copper-induced damage Improved survival under high copper exposure conditions 'We've now seen Telomir-1 generate breakthrough results across some of the most challenging age-related and genetic diseases-including AMD, Wilson's disease, cancer, progeroid and Werner syndromes, and early findings suggesting reversal of key factors in type 2 diabetes,' said Erez Aminov, Chairman and CEO of Telomir. 'In our AMD model, Telomir-1 restored vision and regenerated retinal structure using FDA-recognized surrogate endpoints. In Werner syndrome, it reset the epigenetic clock and reversed hallmarks of accelerated aging. And in Wilson's disease, we saw a reversal of neurological, liver and kidney damage. These results point to the broad therapeutic potential of Telomir-1 across diseases driven by cellular degeneration. We believe this positions Telomir-1 as a powerful new platform for longevity, neuroprotection, and regenerative medicine.' 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease,' added Dr. Angel, Chief Scientific Advisor. 'Its ability to reverse behavioral and neurological dysfunction, normalize histological and functional biomarkers, and extend survival underscores its therapeutic promise across both rare and age-related disorders.' Telomir Pharmaceuticals is currently advancing Telomir-1 through IND-enabling studies and expects to file its first IND for a rare disease indication by year-end, with human clinical trials planned for the first half of 2026. Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information SOURCE: Telomir Pharmaceuticals, Inc View the original press release on ACCESS Newswire
Associated Press
11-06-2025
- Business
- Associated Press
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model
Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival. Building on previous data in Werner syndrome, showing Telomir-1 reset the epigenetic clock, extended telomere length, restored gene expression, reversed muscle loss, and rescued survival-alongside data in Age Related Macular Degeneration (AMD) demonstrating retinal regeneration and restored vision-the drug continues to show broad regenerative potential across rare genetic degenerative diseases MIAMI, FL / ACCESS Newswire / June 11, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the 'Company,' a preclinical-stage biotechnology company focused on reversing biological aging and degenerative diseases, today announced compelling new preclinical data demonstrating that its lead drug candidate, Telomir-1, significantly reversed neurological, hepatic and kidney symptoms in a clinically relevant animal model of Wilson's disease. Wilson's disease is a rare and potentially fatal genetic disorder caused by mutations in the ATP7B gene, which impair the body's ability to eliminate excess copper. As copper builds up-primarily in the liver and brain-it leads to inflammation, tissue damage, and multi-organ dysfunction. Patients may experience liver failure, psychiatric disturbances, tremors, and progressive neurological decline. Current treatments involve lifelong copper chelation or liver transplantation, highlighting the urgent need for safer, disease-modifying therapies. These new results build on earlier in vitro studies that confirmed Telomir-1's high binding affinity for copper and its ability to exchange and regulate key ions. The current in vivo findings now confirm that Telomir-1's copper-regulating properties translate into meaningful behavioral, physiological and histological improvements in a genetic animal model of Wilson's disease. In the ATP7B C271X -/- zebrafish model, which mimics human Wilson's disease Telomir-1 demonstrated dose-dependent and statistically significant reversal of major disease features: Key Findings from the Study: 'We've now seen Telomir-1 generate breakthrough results across some of the most challenging age-related and genetic diseases-including AMD, Wilson's disease, cancer, progeroid and Werner syndromes, and early findings suggesting reversal of key factors in type 2 diabetes,' said Erez Aminov, Chairman and CEO of Telomir. 'In our AMD model, Telomir-1 restored vision and regenerated retinal structure using FDA-recognized surrogate endpoints. In Werner syndrome, it reset the epigenetic clock and reversed hallmarks of accelerated aging. And in Wilson's disease, we saw a reversal of neurological, liver and kidney damage. These results point to the broad therapeutic potential of Telomir-1 across diseases driven by cellular degeneration. We believe this positions Telomir-1 as a powerful new platform for longevity, neuroprotection, and regenerative medicine.' 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease,' added Dr. Angel, Chief Scientific Advisor. 'Its ability to reverse behavioral and neurological dysfunction, normalize histological and functional biomarkers, and extend survival underscores its therapeutic promise across both rare and age-related disorders.' Telomir Pharmaceuticals is currently advancing Telomir-1 through IND-enabling studies and expects to file its first IND for a rare disease indication by year-end, with human clinical trials planned for the first half of 2026. Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya [email protected] (786) 396-6723 SOURCE: Telomir Pharmaceuticals, Inc press release
Scottish Sun
04-06-2025
- Business
- Scottish Sun
Timo Werner ‘available for just £3MILLION' this summer as Chelsea and Spurs flop suffers ultimate fall from grace
TIM TO GO Timo Werner 'available for just £3MILLION' this summer as Chelsea and Spurs flop suffers ultimate fall from grace TIMO WERNER is available for just £3million this summer. The German, 29, has spent the last 18 months on loan at Tottenham from RB Leipzig. Advertisement 3 Timo Werner struggled to make an impact at Tottenham Credit: The Times With Spurs having unsurprisingly opted against making the switch permanent, Werner is set to be on the move again this summer. According to German outlet Bild, RB Leipzig are willing to flog the forward for just £3.4m. Werner still has a year remaining on his contract in Germany, having rejoined the club from Chelsea in 2022. His last appearance for RB Leipzig came 539 days ago, having since twice joined Spurs on loan. Advertisement READ MORE IN FOOTBALL COUPLE GOALS Declan Rice and Wag make rare public appearance after abuse from cruel trolls The former Champions League winner failed to score in 18 Prem appearances this season - and also faced boss Ange Postecoglou's wrath following the 1-1 Europa League draw with Rangers in December. The Aussie, 59, said after hooking Werner at half-time: "When you've got 18-year-olds in the team, it's not acceptable to me. "I said that to Timo, he's a German international. In the moment we're in right now – it's not like we've got many options, I need everyone to at least be going out there and trying to give the best of themselves. "His performance in the first half wasn't acceptable. We need everybody, including him, to be contributing because we don't have the depth to leave people out if they perform poorly. Advertisement BEST ONLINE CASINOS - TOP SITES IN THE UK "I expect a level of performance from some of the senior guys, and tonight wasn't that." Following a hamstring injury suffered in January, Werner played just eight more minutes for Spurs. Ruthless Postecoglou tells Werrner 'I'm not worried about bruised egos' after slamming 'unacceptable' Tottenham star 3 Advertisement TRANSFER NEWS LIVE: ALL THE LATEST FROM THE SUMMER WINDOW His last appearance came in the 1-0 defeat to Manchester City on February 26. Werner was unregistered from Tottenham's Europa League squad ahead of the knockout rounds. But courtesy of making five appearances during the league phase, Werner did pick up a medal. Advertisement Following the final in Bilbao, the forward posted two pictures with his medal in addition to a cheeky caption. Werner wrote: "What a Team !! Like I said. I came to win titles. Thank you and good night!!"
